157 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Thursday’s Close
NVO Novo Nordisk A/S $47.64 $114.84B Downtrend
Article Searches
Orexigen Struggles as Contrave Commercialization Costs Rise http://www.zacks.com/stock/news/287853/orexigen-struggles-as-contrave-commercialization-costs-rise?cid=CS-ZC-FT-287853 Jan 04, 2018 - Orexigen (OREX) hurt by higher commercialization costs related to Contrave.
Can Merck Regain its Mojo in 2018 After an Unimpressive '17? http://www.zacks.com/stock/news/287654/can-merck-regain-its-mojo-in-2018-after-an-unimpressive-17?cid=CS-ZC-FT-287654 Jan 03, 2018 - Merck's (MRK) shares declined in 2017 against an increase witnessed by the large-cap pharma industry. It remains to be seen if the company regains momentum in 2018.
5 Reasons to Invest in Novo Nordisk (NVO) Stock Right Now http://www.zacks.com/stock/news/287540/5-reasons-to-invest-in-novo-nordisk-nvo-stock-right-now?cid=CS-ZC-FT-287540 Jan 02, 2018 - Let's take a look at few factors that help in determining if Novo Nordisk (NVO) will be a good investment in 2018.
The Zacks Analyst Blog Highlights: Johnson and Johnson, AbbVie, Roche's, AstraZeneca and Novo-Nordisk A/S http://www.zacks.com/stock/news/287430/the-zacks-analyst-blog-highlights-johnson-and-johnson-abbvie-roches-astrazeneca-and-novo-nordisk-a-s?cid=CS-ZC-FT-287430 Jan 02, 2018 - The Zacks Analyst Blog Highlights: Johnson and Johnson, AbbVie, Roche's, AstraZeneca and Novo-Nordisk A/S
4 Large-Cap Pharma Stocks That Outperformed the S&P This Year http://www.zacks.com/stock/news/287406/4-large-cap-pharma-stocks-that-outperformed-the-sp-this-year?cid=CS-ZC-FT-287406 Dec 29, 2017 - We take a look at a few Large Cap stocks, which have surpassed the S&P 500 index in 2017 due to upsides on both regulatory and pipeline fronts.
3 Top Pharmaceutical Dividend Stocks to Buy Now https://www.fool.com/investing/2017/12/19/3-top-pharmaceutical-dividend-stocks-to-buy-now.aspx?source=iedfolrf0000001 Dec 19, 2017 - Looking for income from the pharmaceutical industry? Start with these three companies.
Novo Nordisk's (NVO) Semaglutide Gets Positive CHMP Opinion http://www.zacks.com/stock/news/286298/novo-nordisks-nvo-semaglutide-gets-positive-chmp-opinion?cid=CS-ZC-FT-286298 Dec 18, 2017 - Novo Nordisk (NVO) announced that the Committee for Medicinal Products for Human Use has adopted a positive opinion recommending marketing authorisation of semaglutide for the treatment of adults with type II diabetes mellitus.
Lilly Issues Guidance for 2018, New Drugs to Drive Top Line http://www.zacks.com/stock/news/285963/lilly-issues-guidance-for-2018-new-drugs-to-drive-top-line?cid=CS-ZC-FT-285963 Dec 14, 2017 - Eli Lilly (LLY) issues financial guidance for 2018 and also reaffirms the previously issued 2017 projection as well as its long-term expectations.
Foreign Stock Roundup: Bank of Montreal Q4 Earnings Decline, Rio Tinto Lowers '17 Capital Spending Target http://www.zacks.com/stock/news/285502/foreign-stock-roundup-bank-of-montreal-q4-earnings-decline-rio-tinto-lowers-17-capital-spending-target?cid=CS-ZC-FT-285502 Dec 11, 2017 - Investors in Europe remained focused on Brexit negotiations and the Senate's decision to approve a new tax Bill last week.
Pharma Stock Roundup: FDA Nod for NVO's Ozempic, Second Indication for Lilly's Taltz http://www.zacks.com/stock/news/285327/pharma-stock-roundup-fda-nod-for-nvos-ozempic-second-indication-for-lillys-taltz?cid=CS-ZC-FT-285327 Dec 08, 2017 - FDA approval for Novo Nordisk's (NVO) type II diabetes drug, a second indication for Lilly's Taltz, and the approval of the first Herceptin biosimilar were the key highlights this week.

Pages: 1...5678910111213141516

<<<Page 10>